MIT Center for Biomedical Innovation

Ensuring ACCESS TO SAFE AND EFFECTIVE MEDICINES FOR ALL is a complex challenge that requires innovation and collaboration.
MIT CBI is a COLLABORATION ENGINE that brings together the excellence of MIT researchers with stakeholders across the healthcare value chain.
Collaboratively, MIT CBI DESIGNS, TESTS, and IMPLEMENTS ways to ensure global access to safe and effective medicines.

CBI provides integrated solutions to global health

CBI Activities

Collaboration

MIT CBI is home to the Biomanufacturing Consortium (BioMAN), and the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB). These pre-competitive programs provide a safe haven where industry, academia, and government collaboratively address challenges in manufacturing, delivery, and access to biologics through focused events and projects that address key challenges in biomanufacturing.

See our Collaboration

Education

MIT CBI has developed a number of biomanufacturing-related educational offerings including a residential MIT course, an on-line course on the principles of manufacturing protein and antibody drugs, and a short course on vaccine manufacturing offered jointly with University College London. We have developed a blended learning course for the training of cell therapy manufacturing personnel which will combine online learning with hands-on training.

See our Education

Research

MIT CBI research projects focus on biomanufacturing process innovation for production of biologic medicines including monoclonal antibodies, vaccines, viral vectors, and cell therapies. Our main research areas include process analytical technologies, biomanufacturing data analytics, advanced process modeling and control, and continuous manufacturing.

See our Research

Upcoming Events

No event found!

View All Events

Latest News & Research

RFP 2024 Announced

MIT Center for Biomedical Innovation and the Coca-Cola Company announced the next request for proposals (RFP) with an application deadline of May…
FDA funds Center for Continuous mRNA Manufacturing

Researchers from MIT have received an award of $82 million over 3 years from the Food & Drug Administration…
CAACB Publishes on NGS

The Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) collected historical data from 20 biopharmaceutical industry members on their…

View All News

Our Team

CBI’s core strength is in our team’s cross-cutting experience and expertise in medicine, biology, chemistry, biomanufacturing, academic & clinical research, economics, engineering, data analytics, regulatory science and public policy.

Meet the Team

Our Members

Our members and collaborators are leading stakeholders across the global healthcare value chain, from R&D and manufacturing to delivery and reimbursement.